Aladar Szalay Sells 14,331 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43. Following the completion of the transaction, the insider now owns 1,285,794 shares in the company, valued at $4,538,852.82. The sale was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Trading Down 0.9 %

Shares of NASDAQ GNLX traded down $0.03 during midday trading on Wednesday, reaching $3.45. The company had a trading volume of 137,205 shares, compared to its average volume of 125,442. The business’s 50-day simple moving average is $5.95 and its 200 day simple moving average is $11.00. Genelux Co. has a 1 year low of $3.26 and a 1 year high of $40.98.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Friday, March 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). On average, analysts forecast that Genelux Co. will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GNLX. Woodward Diversified Capital LLC raised its holdings in shares of Genelux by 2,326.2% during the fourth quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after purchasing an additional 1,037,663 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Genelux by 1,660.1% in the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after purchasing an additional 925,258 shares during the period. Provident Wealth Management LLC acquired a new stake in shares of Genelux in the third quarter valued at about $8,211,000. AMG National Trust Bank acquired a new stake in shares of Genelux in the third quarter valued at about $1,233,000. Finally, Bank of New York Mellon Corp grew its position in shares of Genelux by 476.6% in the third quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company’s stock valued at $1,321,000 after purchasing an additional 44,584 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. HC Wainwright dropped their price objective on shares of Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Benchmark reiterated a “speculative buy” rating and set a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.